<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-144492</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Why consider treatment with liraglutide in patients with type 2 diabetes?</dc:title>
<dc:description xml:lang="en">Liraglutide is a GLP-1 receptor agonist indicated for the treatment of type 2 diabetes. This drug has an excellent efficacy/safety profile and differential properties, as well as beneficial effects on several parameters of beta cell function (proinsulin ratio: insulin, HOMA-B, first and second insulin secretion phase and maximum insulin secretion, HOMA-IR) that equal or surpass those of its comparators. When added to monotherapy or in oral antidiabetic drug combination therapy, this drug reduces HbA1c by 1.0-1.5%, achieving a target of &lt; 7% in 59% to 71% of patients. Liraglutide significantly reduced fasting blood glucose concentrations (28-43 mg/dL) and postprandial blood glucose levels (32-49 mg/dL) compared with other oral agents, insulin glargine, and exenatide. Liraglutide induces significant weight loss in contrast with the weight gain observed with active comparators (rosiglitazone + 2.1kg; glimepiride + 1.2 kg; glargine + 1.6 kg), except exenatide; this weight loss is especially due to loss of abdominal fat. The incidence of hypoglycemia is very low (0.03-1.9 events/year), almost always occurring in patients receiving treatment with sulfonylureas, and is similar to that observed with metformin or rosiglitazone and is lower than that reported for glimepiride. Liraglutide also has beneficial effects on several cardiovascular risk factors. A retrospective analysis of severe cardiovascular events in phase 2-3 studies has revealed an incidence of 0.73 (95% CI, 0.38-1.41) versus its comparator. These data confirm liraglutide as a highly attractive alternative in combination therapy after metformin failure, even compared with insulin therapy, at any stage of the treatment of type 2 diabetes (AU)</dc:description>
<dc:creator>Ampudia Blasco, F Javier</dc:creator>
<dc:creator>Jodar, Esteban</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Liraglutida es un agonista del receptor de GLP-1, indicado en el tratamiento de la diabetes tipo 2, con un excelente balance eficacia/seguridad y características diferenciales. Liraglutida tiene efectos positivos sobre diversos parámetros de función de las células beta (ratio proinsulina: insulina, HOMA-B, primera y segunda fase de secreción y secreción máxima de insulina, HOMA-IR) que igualan o superan a las de sus comparadores. Añadida a monoterapia o terapia oral combinada con agentes orales produce reducciones de HbA1c de 1,0-1,5%, alcanzando un objetivo &lt; 7% en un 59-71% de los pacientes. Liraglutida reduce significativamente la glucemia plasmática en ayunas (28-43 mg/dl) y la glucemia posprandial (32-49 mg/dl) frente a otras terapias orales, insulina glargina o exenatida. Liraglutida induce pérdida significativa de peso respecto a la ganancia observada con comparadores activos (rosiglitazona + 2,1 kg; glimepirida + 1,2 kg; glargina + 1,6 kg), salvo exenatida, atribuida especialmente a pérdida de masa grasa abdominal. La incidencia de hipoglucemia es muy baja (0,03-1,9 episodios/año), casi siempre en pacientes en tratamiento con sulfonilureas y similar a la observada con metformina o rosiglitazona, y menor a la reportada con glimepirida. Liraglutida tiene, además, efectos beneficiosos sobre diversos factores de riesgo cardiovascular. El análisis retrospectivo de episodios cardiovasculares graves en los estudios de fases II-III ha mostrado una incidencia de 0,73 (inter-valo de confianza del 95%, 0,38-1,41) frente al comparador. En consecuencia, liraglutida se confirma como una alternativa muy atractiva a combinar tras el fracaso de metformina, incluso frente a la insulinización, en cualquier estadio del tratamiento de la diabetes tipo 2 (AU)</dc:description>
<dc:source>Endocrinol Nutr;60(supl.2): 8-14, oct. 2013. graf</dc:source>
<dc:identifier>ibc-144492</dc:identifier>
<dc:title xml:lang="es">¿Por qué plantear el tratamiento con liraglutida en los pacientes con diabetes tipo 2?</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d52846^s22079</dc:subject>
<dc:subject>^d37656^s22021</dc:subject>
<dc:subject>^d50567^s22079</dc:subject>
<dc:subject>^d54857</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d23862^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201310</dc:date>
</metadata>
</record>
</ibecs-document>
